Ribo Life Science advances its lipid-disorder pipeline with an EU Phase I trial application for SR122, a dual-target siRNA candidate targeting ApoC3 and PCSK9 to address complex cardiovascular risks.
Ribo announced on 10 November 2026 the EU clinical trial application for a Phase I study of its dual-target siRNA drug SR122, strengthening its lipid-disorder pipeline alongside Phase II studies of RBD5044. This is routine early-stage pipeline progress without figures, trial results or revenue impact, so it is unlikely to move the share price materially in the coming days.
Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals announced on 10 November 2026 the submission of a Phase I clinical trial application in the EU for SR122. The dual-target siRNA therapeutic is designed to treat mixed dyslipidemia and severe hypertriglyceridemia by simultaneously inhibiting ApoC3 and PCSK9 pathways.
No. The article describes only a clinical trial application for an early Phase I study in healthy volunteers; no revenue, sales or financial figures are mentioned.